Cell-based interventions to halt autoimmunity in type 1 diabetes mellitus

Clinical and Experimental Immunology

Volumn 171, Issue 2, 2013, Pages 135-146

  Barcala Tabarrozzi, A E ^a   Castro, C N ^a   Dewey, R A ^b   Sogayar, M C ^c   Labriola, L ^c   Perone, M J ^a  

^a Instituto de Investigación en Biomedicina de Buenos Aires   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

cells; Dendritic cells; Macrophages; Stem cells; T cells

Indexed keywords

REMESTEMCEL L; RITUXIMAB; TEPLIZUMAB;

ADAPTIVE IMMUNITY; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELL THERAPY; CLINICAL TRIAL (TOPIC); DENDRITIC CELL; DIABETIC PATIENT; GENETIC ENGINEERING; HUMAN; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; MACROPHAGE; MONOCYTE; NATURAL KILLER CELL; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; STEM CELL TRANSPLANTATION;

ANIMALS; AUTOIMMUNITY; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; HUMANS; INSULIN; INSULIN-SECRETING CELLS; MICE; MICE, INBRED NOD; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES, REGULATORY;

EID: 84872162891     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12019     Document Type: Article

References (111)

1. Okada H, Kuhn C, Feillet H, Bach JF. The 'hygiene hypothesis' for autoimmune and allergic diseases: an update. Clin Exp Immunol 2010; 160:1-9.
2. Patterson CC, Dahlquist GG, Gyurus E, Green A, Soltesz G. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 2009; 373:2027-2033.
3. Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol 2009; 155:173-181.
4. Turley S, Poirot L, Hattori M, Benoist C, Mathis D. Physiological beta cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetes model. J Exp Med 2003; 198:1527-1537.
5. Wen L, Ley RE, Volchkov PY etal. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 2008; 455:1109-1113.
6. Noorchashm H, Lieu YK, Noorchashm N etal. I-Ag7-mediated antigen presentation by B lymphocytes is critical in overcoming a checkpoint in T cell tolerance to islet beta cells of nonobese diabetic mice. J Immunol 1999; 163:743-750.
7. Tian J, Zekzer D, Lu Y, Dang H, Kaufman DL. B cells are crucial for determinant spreading of T cell autoimmunity among beta cell antigens in diabetes-prone nonobese diabetic mice. J Immunol 2006; 176:2654-2661.
8. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002; 3:944-950.
9. Serreze DV, Chapman HD, Varnum DS etal. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new 'speed congenic' stock of NOD.Ig mu null mice. J Exp Med 1996; 184:2049-2053.
10. Martin S, Wolf-Eichbaum D, Duinkerken G etal. Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N Engl J Med 2001; 345:1036-1040.
11. Hu CY, Rodriguez-Pinto D, Du W etal. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 2007; 117:3857-3867.
12. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H etal. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009; 361:2143-2152.
13. Herold KC, Pescovitz MD, McGee P etal. Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes. J Immunol 2011; 187:1998-2005.
14. Luther SA, Lopez T, Bai W, Hanahan D, Cyster JG. BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis. Immunity 2000; 12:471-481.
15. Carvello M, Petrelli A, Vergani A etal. Inotuzumab ozogamicin murine analog-mediated B-cell depletion reduces anti-islet allo- and autoimmune responses. Diabetes 2012; 61:155-165.
16. Tian J, Zekzer D, Hanssen L, Lu Y, Olcott A, Kaufman DL. Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice. J Immunol 2001; 167:1081-1089.
17. Hussain S, Delovitch TL. Intravenous transfusion of BCR-activated B cells protects NOD mice from type 1 diabetes in an IL-10-dependent manner. J Immunol 2007; 179:7225-7232.
18. Giannoukakis N, Phillips B, Finegold D, Harnaha J, Trucco M. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care 2011; 34:2026-2032.
19. Roep BO, Kallan AA, De Vries RR. Beta-cell antigen-specific lysis of macrophages by CD4 T-cell clones from newly diagnosed IDDM patient. A putative mechanism of T-cell-mediated autoimmune islet cell destruction. Diabetes 1992; 41:1380-1384.
20. Bougneres PF, Carel JC, Castano L etal. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med 1988; 318:663-670.
21. Lampeter EF, Homberg M, Quabeck K etal. Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation. Lancet 1993; 341:1243-1244.
22. Chang JC, Linarelli LG, Laxer JA etal. Insulin-secretory-granule specific T cell clones in human IDDM. J Autoimmun 1995; 8:221-234.
23. Herold KC, Hagopian W, Auger JA etal. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346:1692-1698.
24. Keymeulen B, Vandemeulebroucke E, Ziegler AG etal. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352:2598-2608.
25. Sherry N, Hagopian W, Ludvigsson J etal. Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011; 378:487-497.
26. AbATE Study hOKT3 1(Ala-Ala); teplizumab; treatment of type 1 diabetes-update on clinical trials [Symposia]. In: Proceedings of the 71st Scientific Sessions American Diabetes Association. San Diego, CA, 2011.
27. Christianson SW, Shultz LD, Leiter EH. Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice. Relative contributions of CD4+ and CD8+ T-cells from diabetic versus prediabetic NOD.NON-Thy-1a donors. Diabetes 1993; 42:44-55.
28. Tian J, Olcott AP, Kaufman DL. Antigen-based immunotherapy drives the precocious development of autoimmunity. J Immunol 2002; 169:6564-6569.
29. Katz JD, Benoist C, Mathis D. T helper cell subsets in insulin-dependent diabetes. Science 1995; 268:1185-1188.
30. Chang CL, Chang SL, Lee YM etal. Cytopiloyne, a polyacetylenic glucoside, prevents type 1 diabetes in nonobese diabetic mice. J Immunol 2007; 178:6984-6993.
31. Perone MJ, Bertera S, Shufesky WJ etal. Suppression of autoimmune diabetes by soluble galectin-1. J Immunol 2009; 182:2641-2653.
32. Serreze DV, Chapman HD, Post CM, Johnson EA, Suarez-Pinzon WL, Rabinovitch A. Th1 to Th2 cytokine shifts in nonobese diabetic mice: sometimes an outcome, rather than the cause, of diabetes resistance elicited by immunostimulation. J Immunol 2001; 166:1352-1359.
33. Peng Y, Laouar Y, Li MO, Green EA, Flavell RA. TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes. Proc Natl Acad Sci USA 2004; 101:4572-4577.
34. Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol 2007; 8:191-197.
35. Salomon B, Lenschow DJ, Rhee L etal. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000; 12:431-440.
36. Brusko T, Wasserfall C, McGrail K etal. No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes. Diabetes 2007; 56:604-612.
37. Kukreja A, Cost G, Marker J etal. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002; 109:131-140.
38. Michalek J, Vrabelova Z, Hrotekova Z etal. Immune regulatory T cells in siblings of children suffering from type 1 diabetes mellitus. Scand J Immunol 2006; 64:531-535.
39. Putnam AL, Vendrame F, Dotta F, Gottlieb PA. CD4+CD25high regulatory T cells in human autoimmune diabetes. J Autoimmun 2005; 24:55-62.
40. Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 2005; 54:92-99.
41. Schneider A, Rieck M, Sanda S, Pihoker C, Greenbaum C, Buckner JH. The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J Immunol 2008; 181:7350-7355.
42. Marwaha AK, Crome SQ, Panagiotopoulos C etal. Cutting edge: increased IL-17-secreting T cells in children with new-onset type 1 diabetes. J Immunol 2010; 185:3814-3818.
43. Weber SE, Harbertson J, Godebu E etal. Adaptive islet-specific regulatory CD4 T cells control autoimmune diabetes and mediate the disappearance of pathogenic Th1 cells in vivo. J Immunol 2006; 176:4730-4739.
44. Long SA, Rieck M, Sanda S etal. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function. Diabetes 2012; 61:2340-2348.
45. Putnam AL, Brusko TM, Lee MR etal. Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes 2009; 58:652-662.
46. Tarbell KV, Yamazaki S, Olson K, Toy P, Steinman RM. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med 2004; 199:1467-1477.
47. Tang Q, Henriksen KJ, Bi M etal. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 2004; 199:1455-1465.
48. Fisson S, Djelti F, Trenado A etal. Therapeutic potential of self-antigen-specific CD4+ CD25+ regulatory T cells selected in vitro from a polyclonal repertoire. Eur J Immunol 2006; 36:817-827.
49. Herold KC, Gitelman SE, Masharani U etal. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005; 54:1763-1769.
50. Martin-Orozco N, Chung Y, Chang SH, Wang YH, Dong C. Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells. Eur J Immunol 2009; 39:216-224.
51. Bending D, De la Pena H, Veldhoen M etal. Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. J Clin Invest 2009; 119:565-572.
52. Emamaullee JA, Davis J, Merani S etal. Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes 2009; 58:1302-1311.
53. Van Belle TL, Esplugues E, Liao J, Juntti T, Flavell RA, von Herrath MG. Development of autoimmune diabetes in the absence of detectable IL-17A in a CD8-driven virally induced model. J Immunol 2011; 187:2915-2922.
54. Arif S, Moore F, Marks K etal. Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated beta-cell death. Diabetes 2011; 60:2112-2119.
55. Honkanen J, Nieminen JK, Gao R etal. IL-17 immunity in human type 1 diabetes. J Immunol 2010; 185:1959-1967.
56. Ferraro A, Socci C, Stabilini A etal. Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes 2011; 60:2903-2913.
57. Phillips JM, Parish NM, Raine T etal. Type 1 diabetes development requires both CD4+ and CD8+ T cells and can be reversed by non-depleting antibodies targeting both T cell populations. Rev Diabet Stud 2009; 6:97-103.
58. Toma A, Laika T, Haddouk S etal. Recognition of human proinsulin leader sequence by class I-restricted T-cells in HLA-A*0201 transgenic mice and in human type 1 diabetes. Diabetes 2009; 58:394-402.
59. Coppieters KT, Dotta F, Amirian N etal. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med 2012; 209:51-60.
60. Skowera A, Ellis RJ, Varela-Calvino R etal. CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest 2008; 118:3390-3402.
61. Vincent BG, Young EF, Buntzman AS etal. Toxin-coupled MHC class I tetramers can specifically ablate autoreactive CD8+ T cells and delay diabetes in nonobese diabetic mice. J Immunol 2010; 184:4196-4204.
62. Brauner H, Elemans M, Lemos S etal. Distinct phenotype and function of NK cells in the pancreas of nonobese diabetic mice. J Immunol 2010; 184:2272-2280.
63. Gur C, Porgador A, Elboim M etal. The activating receptor NKp46 is essential for the development of type 1 diabetes. Nat Immunol 2010; 11:121-128.
64. Beilke JN, Kuhl NR, Van Kaer L, Gill RG. NK cells promote islet allograft tolerance via a perforin-dependent mechanism. Nat Med 2005; 11:1059-1065.
65. Roman-Gonzalez A, Moreno ME, Alfaro JM etal. Frequency and function of circulating invariant NKT cells in autoimmune diabetes mellitus and thyroid diseases in Colombian patients. Hum Immunol 2009; 70:262-268.
66. Kis J, Engelmann P, Farkas K etal. Reduced CD4+ subset and Th1 bias of the human iNKT cells in Type 1 diabetes mellitus. J Leukoc Biol 2006; 81:654-662.
67. Lee PT, Putnam A, Benlagha K, Teyton L, Gottlieb PA, Bendelac A. Testing the NKT cell hypothesis of human IDDM pathogenesis. J Clin Invest 2002; 110:793-800.
68. Wilson SB, Kent SC, Patton KT etal. Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature 1998; 391:177-181.
69. Oikawa Y, Shimada A, Yamada S etal. High frequency of valpha24(+) vbeta11(+) T-cells observed in type 1 diabetes. Diabetes Care 2002; 25:1818-1823.
70. Oikawa Y, Shimada A, Yamada S etal. NKT cell frequency in Japanese type 1 diabetes. Ann NY Acad Sci 2003; 1005:230-232.
71. Chatenoud L. Do NKT cells control autoimmunity? J Clin Invest 2002; 110:747-748.
72. Sharif S, Arreaza GA, Zucker P etal. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med 2001; 7:1057-1062.
73. Hong S, Wilson MT, Serizawa I etal. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 2001; 7:1052-1056.
74. Lehuen A, Lantz O, Beaudoin L etal. Overexpression of natural killer T cells protects Valpha14- Jalpha281 transgenic nonobese diabetic mice against diabetes. J Exp Med 1998; 188:1831-1839.
75. Wang B, Geng YB, Wang CR. CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes. J Exp Med 2001; 194:313-320.
76. Shi FD, Flodstrom M, Balasa B etal. Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse. Proc Natl Acad Sci USA 2001; 98:6777-6782.
77. Martin AP, Rankin S, Pitchford S, Charo IF, Furtado GC, Lira SA. Increased expression of CCL2 in insulin-producing cells of transgenic mice promotes mobilization of myeloid cells from the bone marrow, marked insulitis, and diabetes. Diabetes 2008; 57:3025-3033.
78. Calderon B, Suri A, Unanue ER. In CD4+ T-cell-induced diabetes, macrophages are the final effector cells that mediate islet beta-cell killing: studies from an acute model. Am J Pathol 2006; 169:2137-2147.
79. Bradshaw EM, Raddassi K, Elyaman W etal. Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells. J Immunol 2009; 183:4432-4439.
80. Devaraj S, Dasu MR, Rockwood J, Winter W, Griffen SC, Jialal I. Increased Toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab 2008; 93:578-583.
81. Uno S, Imagawa A, Okita K etal. Macrophages and dendritic cells infiltrating islets with or without beta cells produce tumour necrosis factor-alpha in patients with recent-onset type 1 diabetes. Diabetologia 2007; 50:596-601.
82. Hume DA. Macrophages as APC and the dendritic cell myth. J Immunol 2008; 181:5829-5835.
83. Ohnmacht C, Pullner A, King SB etal. Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity. J Exp Med 2009; 206:549-559.
84. Saxena V, Ondr JK, Magnusen AF, Munn DH, Katz JD. The countervailing actions of myeloid and plasmacytoid dendritic cells control autoimmune diabetes in the nonobese diabetic mouse. J Immunol 2007; 179:5041-5053.
85. Chen X, Makala LH, Jin Y etal. Type 1 diabetes patients have significantly lower frequency of plasmacytoid dendritic cells in the peripheral blood. Clin Immunol 2008; 129:413-418.
86. Summers KL, Marleau AM, Mahon JL, McManus R, Hramiak I, Singh B. Reduced IF. N-alpha secretion by blood dendritic cells in human diabetes. Clin Immunol 2006; 121:81-89.
87. Allen JS, Pang K, Skowera A etal. Plasmacytoid dendritic cells are proportionally expanded at diagnosis of type 1 diabetes and enhance islet autoantigen presentation to T-cells through immune complex capture. Diabetes 2009; 58:138-145.
88. Peng R, Li Y, Brezner K, Litherland S, Clare-Salzler MJ. Abnormal peripheral blood dendritic cell populations in type 1 diabetes. Ann NY Acad Sci 2003; 1005:222-225.
89. Zhang M, Tang H, Guo Z etal. Splenic stroma drives mature dendritic cells to differentiate into regulatory dendritic cells. Nat Immunol 2004; 5:1124-1133.
90. Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol 2002; 23:445-449.
91. Perone MJ, Bertera S, Tawadrous ZS etal. Dendritic cells expressing transgenic galectin-1 delay onset of autoimmune diabetes in mice. J Immunol 2006; 177:5278-5289.
92. Jantsch J, Turza N, Volke M etal. Small interfering RNA (siRNA) delivery into murine bone marrow-derived dendritic cells by electroporation. J Immunol Methods 2008; 337:71-77.
93. Dor Y, Brown J, Martinez OI, Melton DA. Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 2004; 429:41-46.
94. Maria-Engler SS, Correa-Giannella ML, Labriola L etal. Co-localization of nestin and insulin and expression of islet cell markers in long-term human pancreatic nestin-positive cell cultures. J Endocrinol 2004; 183:455-467.
95. Ryan EA, Paty BW, Senior PA etal. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54:2060-2069.
96. Wood K. Outlook for longer-lasting islets. Nat Med 2008; 14:1156-1157.
97. Emamaullee JA, Shapiro AM. Interventional strategies to prevent beta-cell apoptosis in islet transplantation. Diabetes 2006; 55:1907-1914.
98. Shapiro AM, Toso C, Imes A etal. Five-year results of islet-alone transplantation match pancreas-alone transplantation with alemtuzumab, Tac/MMF, with strong suppression of auto and alloreativity. Rev Diabet Stud 2011; 8:95-96.
99. Yamamoto T, Mita A, Ricordi C etal. Prolactin supplementation to culture medium improves beta-cell survival. Transplantation 2010; 89:1328-1335.
100. Terra LF, Garay-Malpartida MH, Wailemann RA, Sogayar MC, Labriola L. Recombinant human prolactin promotes human beta cell survival via inhibition of extrinsic and intrinsic apoptosis pathways. Diabetologia 2011; 54:1388-1397.
101. Kroon E, Martinson LA, Kadoya K etal. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol 2008; 26:443-452.
102. Couri CE, Oliveira MC, Stracieri AB etal. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2009; 301:1573-1579.
103. Cyclosporin-induced remission of IDDM after early intervention. Association of 1yr of cyclosporin treatment with enhanced insulin secretion. The Canadian-European Randomized Control Trial Group. Diabetes 1988; 37:1574-1582.
104. Saudek F, Havrdova T, Boucek P, Karasova L, Novota P, Skibova J. Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset. Rev Diabet Stud 2004; 1:80-88.
105. Haller MJ, Wasserfall CH, Hulme MA etal. Autologous umbilical cord blood transfusion in young children with type 1 diabetes fails to preserve C-peptide. Diabetes Care 2011; 34:2567-2569.
106. Zhao Y, Jiang Z, Zhao T etal. Reversal of type 1 diabetes via islet beta cell regeneration following immune modulation by cord blood-derived multipotent stem cells. BMC Med 2012; 10:1-12.
107. Preynat-Seauve O, Krause KH. Stem cell sources for regenerative medicine: the immunological point of view. Semin Immunopathol 2011; 33:519-524.
108. Waldron-Lynch F, Henegariu O, Deng S etal. Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients. Sci Transl Med 2012; 4:118ra12.
109. GlaxoSmithKline and Tolerx announce phase III DEFEND-1 study of otelixizumab in type 1 diabetes did not meet its primary endpoint. 2011. Available at: http://us.gsk.com/html/media-news/pressreleases/2011/2011_pressrelease_10039.htm.
110. Fiorina P, Vezzulli P, Bassi R etal. Near normalization of metabolic and functional features of the central nervous system in type 1 diabetic patients with end-stage renal disease after kidney-pancreas transplantation. Diabetes Care 2012; 35:367-374.
111. Venstrom JM, McBride MA, Rother KI, Hirshberg B, Orchard TJ, Harlan DM. Survival after pancreas transplantation in patients with diabetes and preserved kidney function. JAMA 2003; 290:2817-2823.